Reduced Nicotine Content Cigarettes
PreclinicalSmall molecule
Reduced Nicotine Content Cigarettes is one of 21 small molecule programs targeting Anxiety Disorder. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
16 competitors in Anxiety Disorder
#DrugCompanyPhaseTrials
1Brintellix
TakedaApproved
Vyvanse
TakedaApproved
Adhansia Xr
NovartisApproved
Cymbalta
Jazz PharmaceuticalsApproved
Buspar
Bristol-Myers SquibbApproved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Xanax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Mifeprex
DDanco
Approved
Inderal
WWyeth-Lederle Vaccines
Approved
Valium
Akero TherapeuticsApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMilton S. Hershey Medical Center